Peptide Library

Human study PLS-00052

Circulating levels of MOTS-c in patients with breast cancer treated with metformin.

Randomized controlled trial · Not reported participants enrolled · not included in the assessments (wrong compound)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Circulating levels of MOTS-c in patients with breast cancer treated with metformin.primary · Aging · 2022-12-06 · PMID 36490309 · DOI

Design and participants

Design
Randomized controlled trial
Population
Patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy and trastuzumab, with paired baseline and post-treatment sera.
Conditions
HER2-positive breast cancer
Setting
Neoadjuvant breast cancer treatment trial; setting details not stated in abstract.
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
Research Support, Non-U.S. Gov't (per publication type); funders not named in abstract.
Authors’ conflicts
Not reported in abstract.

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety.

    Monitoring: Not reported in abstract.

    The authors concluded (paraphrased): Metformin added to neoadjuvant chemotherapy/trastuzumab did not significantly change circulating MOTS-c, possibly because metformin does not target skeletal muscle. Further studies are needed.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: MOTS-c was not administered; it was measured only as an endogenous biomarker in response to metformin.
    • abstract only: Only the abstract is available; sample sizes, numeric results and methods details are not reported.
    • inappropriate endpoint: The outcome is a circulating peptide level measured by a commercial ELISA, a surrogate rather than a patient-important outcome.
    • inappropriate population: The population is HER2-positive breast cancer patients, not adults with metabolic disease or recipients of MOTS-c.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • arms: PMID 36490309, abstract (sentences 4-5) · extracted by AI (automated, not verified by a person) · abstract only
    • author_conclusion: PMID 36490309, abstract (sentences 7-8) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 36490309, abstract (sentence 4) · extracted by AI (automated, not verified by a person) · abstract only
    • funding: PMID 36490309, title (publication types) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 36490309, abstract (sentences 4-7) · extracted by AI (automated, not verified by a person) · abstract only
    • outcomes: PMID 36490309, abstract (sentences 5-6) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 36490309, abstract (sentence 4) · extracted by AI (automated, not verified by a person) · abstract only
    • results: PMID 36490309, abstract (sentences 5-6) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).